By IDSE News Staff
The FDA approved the second monoclonal antibody (mAb) for the prevention of respiratory syncytial virus (RSV) in neonates and infants, clesrovimab-cfor (Enflonsia, Merck).
Clesrovimab-cfor is indicated for all newborns and infants who are born during or entering their first RSV season. The injection is only one dose of 105 mg, no matter what the infant’s weight, compared with the earlier approved mAb nirsevimab (Beyfortus, AstraZeneca), which has weight-based doses of 50